China's National Medical Products Administration has approved a Phase III trial of InnoCare Pharma’s ICP-248 (Mesutoclax) ...
Despite research showing the benefits of circulating tumor DNA as an indicator of disease remission in B-cell lymphoma, ...
Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...
F. Hoffmann-La Roche Ltd (Roche) has a rich history of antibody therapies to treat cancers (malignancies) that affect B cells (a type of white blood cell), including non-Hodgkin lymphoma and ...
Others are faster growing ('aggressive'), for example, diffuse large B-cell lymphoma, Burkitt’s lymphoma ... for these patients (around 60% will be cured), still approximately 30—40% of ...
The Cure keyboardist Roger O’Donnell revealed his lymphoma diagnosis in a series of posts on X Sunday, Sept. 1, in honor of ...
Ciltacabtagene autoleucel (cilta-cel) is an FDA-approved anti–B-cell maturation ... of CAR T-cell therapy. An additional case of indolent CD4+ cytotoxic CAR+ T-cell lymphoma in the small ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback